GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (NAS:SNOA) » Definitions » FCF Yield %

SNOA (Sonoma Pharmaceuticals) FCF Yield % : 2.54 (As of Mar. 27, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Sonoma Pharmaceuticals FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Sonoma Pharmaceuticals's Trailing 12-Month Free Cash Flow is $0.13 Mil, and Market Cap is $5.07 Mil. Therefore, Sonoma Pharmaceuticals's FCF Yield % for today is 2.54%.

The historical rank and industry rank for Sonoma Pharmaceuticals's FCF Yield % or its related term are showing as below:

SNOA' s FCF Yield % Range Over the Past 10 Years
Min: -616.82   Med: -53.75   Max: 4.43
Current: 2.54


During the past 13 years, the highest FCF Yield % of Sonoma Pharmaceuticals was 4.43%. The lowest was -616.82%. And the median was -53.75%.

SNOA's FCF Yield % is ranked better than
66.21% of 1030 companies
in the Drug Manufacturers industry
Industry Median: 0.105 vs SNOA: 2.54

Sonoma Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2024 was 15.80%.


Sonoma Pharmaceuticals FCF Yield % Historical Data

The historical data trend for Sonoma Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals FCF Yield % Chart

Sonoma Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -55.00 -22.80 -35.27 -133.14 -93.09

Sonoma Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -179.10 23.90 -90.98 31.92 51.81

Competitive Comparison of Sonoma Pharmaceuticals's FCF Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sonoma Pharmaceuticals's FCF Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Sonoma Pharmaceuticals's FCF Yield % falls into.


';

Sonoma Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Sonoma Pharmaceuticals's FCF Yield % for the fiscal year that ended in Mar. 2024 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-2.415 / 2.59428
=-93.09%

Sonoma Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=0.563 * 4 / 4.34704
=51.81%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sonoma Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Sonoma Pharmaceuticals FCF Yield % Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonoma Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
Executives
Chad Norman White officer: Interim CFO 645 MOLLY LANE, SUITE 150, WOODSTOCK GA 30189
Jerome J Dvonch officer: Chief Financial Officer 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Robert Grant Edwards officer: Chief Financial Officer 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Poggetto John Dal officer: Chief Financial Officer 1129 N. MCDOWELL BLVD, PETALUMA CA 94954
Amy Moss Trombly officer: Interim CEO 1314 MAIN STREET, SUITE 102, LOUSIVILLE CO 80027
Frederick J Sandford director, officer: CEO and Interim CFO C/O SONOMA PHARMACEUTICALS, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Philippe Weigerstorfer director 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Robert E Miller officer: Chief Financial Officer 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
James J Schutz director, officer: Chief Operating Officer 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Marc Umscheid officer: Chief Strategy/Mkt Officer OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Robert Allen Northey officer: Exec. VP of Res & Devlpment C/O OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Sharon Surrey Barbari director 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Russell Joseph Harrison director OCULUS INNOVATIVE SCIENCES, INC., 1129 NORTH MCDOWELL BLVD., PETALUMA CA 94954
John Mclaughlin director OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Sameer Harish other: Officer of Subsidiary (1) RUTHIGEN, INC., 1129 N. MCDOWELL BLVD, PETALUMA CA 94954